DK1562573T3 - Farmaceutiske pellets omfattende tamsulosin og en fremgangsmåde til fremstilling deraf - Google Patents

Farmaceutiske pellets omfattende tamsulosin og en fremgangsmåde til fremstilling deraf

Info

Publication number
DK1562573T3
DK1562573T3 DK02786241T DK02786241T DK1562573T3 DK 1562573 T3 DK1562573 T3 DK 1562573T3 DK 02786241 T DK02786241 T DK 02786241T DK 02786241 T DK02786241 T DK 02786241T DK 1562573 T3 DK1562573 T3 DK 1562573T3
Authority
DK
Denmark
Prior art keywords
tamsulosin
preparation
pharmaceutical pellets
pellets
pharmaceutical
Prior art date
Application number
DK02786241T
Other languages
English (en)
Inventor
Johannes Jan Platteeuw
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1562573(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Application granted granted Critical
Publication of DK1562573T3 publication Critical patent/DK1562573T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02786241T 2002-11-14 2002-12-12 Farmaceutiske pellets omfattende tamsulosin og en fremgangsmåde til fremstilling deraf DK1562573T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/293,940 US7018658B2 (en) 2002-11-14 2002-11-14 Pharmaceutical pellets comprising tamsulosin

Publications (1)

Publication Number Publication Date
DK1562573T3 true DK1562573T3 (da) 2006-08-21

Family

ID=23131212

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02786241T DK1562573T3 (da) 2002-11-14 2002-12-12 Farmaceutiske pellets omfattende tamsulosin og en fremgangsmåde til fremstilling deraf
DK200300005U DK200300005U3 (da) 2002-11-14 2003-01-08 Farmaceutiske pellets indeholdende tamsulosin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK200300005U DK200300005U3 (da) 2002-11-14 2003-01-08 Farmaceutiske pellets indeholdende tamsulosin

Country Status (23)

Country Link
US (1) US7018658B2 (da)
EP (1) EP1562573B1 (da)
JP (1) JP5405710B2 (da)
AT (2) ATE323478T1 (da)
AU (3) AU2002351451A1 (da)
BE (1) BE1015435A4 (da)
CA (1) CA2415840C (da)
CH (1) CH696419A5 (da)
CZ (1) CZ13341U1 (da)
DE (2) DE20219293U1 (da)
DK (2) DK1562573T3 (da)
ES (1) ES2257589T3 (da)
FI (1) FI5842U1 (da)
FR (1) FR2847166B1 (da)
GB (1) GB2395125B (da)
HU (1) HUP0500832A3 (da)
NL (1) NL1022151C2 (da)
NO (1) NO20052860L (da)
PL (1) PL206083B1 (da)
PT (1) PT1562573E (da)
SI (1) SI21394A2 (da)
WO (2) WO2004043449A1 (da)
ZA (1) ZA200503696B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
EP1476139B1 (en) * 2002-02-21 2017-05-17 Valeant Pharmaceuticals Luxembourg S.à.r.l. Controlled release dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US20060147531A1 (en) * 2003-07-01 2006-07-06 Mojca Segula Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
AU2003286415A1 (en) * 2003-12-03 2005-06-24 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100615952B1 (ko) * 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1618873B1 (de) * 2004-07-14 2007-06-06 Siegfried Generics International AG Granulat zur kontrollierten Freisetzung von Tamsulosin, enthaltend Alginat
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR100745515B1 (ko) * 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
WO2007131804A1 (en) * 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2047847A1 (en) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising tamsulosin
EP2217228B1 (en) * 2007-10-12 2012-04-04 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising tamsulosin
US20110244033A1 (en) * 2008-12-09 2011-10-06 Denny Johan Marijn Van Den Heuvel Tamsulosin pellets for fixed dose combination
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
JP2012533586A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化安定化された不正使用防止剤形
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
KR20160021095A (ko) * 2013-06-21 2016-02-24 욱크하르트 리미티드 탐술로신 또는 이의 염의 약학 조성물
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
CZ2015225A3 (cs) * 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN105287395A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
ES2933177T3 (es) 2016-03-31 2023-02-02 Hanmi Pharm Ind Co Ltd Preparación de cápsulas compuestas, que contienen tadalafilo y tamsulosina, y que tienen una estabilidad y una tasa de elución mejoradas
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
CA3235733A1 (en) 2021-10-25 2023-05-04 Farmalider, S.A. Tadalafil oral suspension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
JPH07316077A (ja) * 1994-05-20 1995-12-05 Sumitomo Pharmaceut Co Ltd 腸溶性コーティング用組成物
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
AR022348A1 (es) * 1999-08-09 2002-09-04 Astellas Pharma Inc Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
WO2001015668A1 (en) * 1999-09-02 2001-03-08 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
FR2847166A1 (fr) 2004-05-21
FI5842U1 (fi) 2003-07-03
AU2002351451A1 (en) 2004-06-03
WO2004043449A1 (en) 2004-05-27
GB2395125B (en) 2007-06-06
ZA200503696B (en) 2006-08-30
ATE323478T1 (de) 2006-05-15
NO20052860L (no) 2005-08-10
US20040096502A1 (en) 2004-05-20
CA2415840A1 (en) 2004-05-14
EP1562573B1 (en) 2006-04-19
FIU20020500U0 (fi) 2002-12-16
ES2257589T3 (es) 2006-08-01
JP2006508960A (ja) 2006-03-16
HUP0500832A2 (en) 2007-07-30
CZ13341U1 (cs) 2003-06-02
AT6542U1 (de) 2003-12-29
HUP0500832A3 (en) 2009-12-28
US7018658B2 (en) 2006-03-28
DK200300005U3 (da) 2003-04-25
DE60210828D1 (de) 2006-05-24
AU2003288083A1 (en) 2004-06-03
GB0229021D0 (en) 2003-01-15
GB2395125A (en) 2004-05-19
PL357856A1 (en) 2004-05-17
CH696419A5 (de) 2007-06-15
DE20219293U1 (de) 2003-06-05
SI21394A2 (sl) 2004-06-30
EP1562573A1 (en) 2005-08-17
DE60210828T2 (de) 2006-10-19
FR2847166B1 (fr) 2005-06-10
JP5405710B2 (ja) 2014-02-05
NO20052860D0 (no) 2005-06-13
CA2415840C (en) 2008-11-18
AU2003200059B2 (en) 2008-07-03
WO2004043448A1 (en) 2004-05-27
BE1015435A4 (nl) 2005-04-05
AU2003200059A1 (en) 2004-06-03
PL206083B1 (pl) 2010-06-30
NL1022151C2 (nl) 2004-05-18
PT1562573E (pt) 2006-07-31

Similar Documents

Publication Publication Date Title
DK1562573T3 (da) Farmaceutiske pellets omfattende tamsulosin og en fremgangsmåde til fremstilling deraf
DK1480622T3 (da) Farmaceutiske, granulære immediate release-præparater og en kontinuert fremgangsmåde til fremstilling deraf
DK1534237T3 (da) Oralt oplöselige tabletter og fremgangsmåde til fremstilling deraf
NO20031776L (no) Null-boringskomplettering og produksjonssystem
NO20055173D0 (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
DK1509266T3 (da) System omfattende en dyse og et holdersystem
ATE321544T1 (de) Tamsulosin tabletten
IS7369A (is) Aðferð og tæki til örflögunýmyndunar
ATE555809T1 (de) Pharmezeutische anti-tnf-alpha antikörper formulierung
DK1589825T3 (da) Komprimeret tyggegummitablet
IS7715A (is) Nýjar lyfjasamsetningar úr módafíníl
IS7594A (is) Laxófoxifen tafla og húðun hennar
ATE388693T1 (de) Wohlschmeckende kautablette
NO20043333L (no) Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
DK1849468T3 (da) Farmaceutisk sammensætning omfattende roflumilast og levocetirizin
DK1572950T3 (da) Enkeltdomæne TDF-relaterede forbindelser og analoger deraf
DK1639107T3 (da) Forbedrede proteaser og fremgangsmåder til fremstilling deraf
IS7846A (is) Aðferð til að framleiða lyfjafræðilega virkt efnasamband og til að framleiða milliefni þess
IS7581A (is) Lyfjasamsetning
SI1562573T1 (sl) Farmacevtske pilule, ki vsebujejo tamsulozin in postopek priprave le teh
AU156818S (en) Pharmaceutical tablet